Expert Views from Pharma and Biotech Industry Leaders
Refine Search
Biosimilars
An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary of Biocon. 7 April 2025
Pharmaceutical
Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 4 April 2025
Pharmaceutical
Budget limitations and health crises are a constant in several countries in the Americas, impacting not only the population, but also the pharmaceutical industry which, in some cases, does not benefit from solid regulatory bases to promote research or regulate innovative medicines, given that there are many cumbersome procedures and financial instability. 18 March 2025
Pharmaceutical
An Expert View from Rob Abbott, chief executive and executive director of ISPOR — The Professional Society for Health Economics and Outcomes Research (HEOR), a nonprofit advancing HEOR excellence to improve decision-making for health globally. 10 March 2025
Pharmaceutical
Rare Disease Day, held annually on 28th February, raises awareness of people living with rare diseases across the world, their families, and their carers. The key aims of the campaign are to achieve equitable access to diagnosis, treatment, and social opportunity for those affected by rare diseases. 28 February 2025
Pharmaceutical
An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International. 12 February 2025
Biotechnology
In this Expert View column, Abbas Kazimi, chief business officer of Nimbus Therapeutics, discusses the advantages of a “failing fast” business strategy and the infrastructures and protocols that must be in place to support rapid, objective decision-making and portfolio management. 29 January 2025
Pharmaceutical
An Expert View from Kevin Wild, head of pre-sales at software company Syniti. 23 January 2025
Biotechnology
Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues. 30 December 2024
Pharmaceutical
The pharmacovigilance (PV) teams within the pharmaceutical industry currently report allocating 40 to 85% of budgets towards case processing. With case processing volumes growing at a rate of 10 to 15% annually, life sciences organizations are aiming to reduce costs and automate time-consuming processes while maintaining or improving quality. 9 December 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Pharmaceutical
An Expert View from the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar. 13 August 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
An Expert View from William Hind of Alpharmaxim and Lisa Campbell of SSI Strategy. 18 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Biosimilars
An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary of Biocon. 7 April 2025
Pharmaceutical
Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 4 April 2025
Pharmaceutical
Budget limitations and health crises are a constant in several countries in the Americas, impacting not only the population, but also the pharmaceutical industry which, in some cases, does not benefit from solid regulatory bases to promote research or regulate innovative medicines, given that there are many cumbersome procedures and financial instability. 18 March 2025
Pharmaceutical
An Expert View from Rob Abbott, chief executive and executive director of ISPOR — The Professional Society for Health Economics and Outcomes Research (HEOR), a nonprofit advancing HEOR excellence to improve decision-making for health globally. 10 March 2025
Pharmaceutical
Rare Disease Day, held annually on 28th February, raises awareness of people living with rare diseases across the world, their families, and their carers. The key aims of the campaign are to achieve equitable access to diagnosis, treatment, and social opportunity for those affected by rare diseases. 28 February 2025
Pharmaceutical
An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International. 12 February 2025
Biotechnology
In this Expert View column, Abbas Kazimi, chief business officer of Nimbus Therapeutics, discusses the advantages of a “failing fast” business strategy and the infrastructures and protocols that must be in place to support rapid, objective decision-making and portfolio management. 29 January 2025
Pharmaceutical
An Expert View from Kevin Wild, head of pre-sales at software company Syniti. 23 January 2025
Biotechnology
Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues. 30 December 2024
Pharmaceutical
The pharmacovigilance (PV) teams within the pharmaceutical industry currently report allocating 40 to 85% of budgets towards case processing. With case processing volumes growing at a rate of 10 to 15% annually, life sciences organizations are aiming to reduce costs and automate time-consuming processes while maintaining or improving quality. 9 December 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Pharmaceutical
An Expert View from the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar. 13 August 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
An Expert View from William Hind of Alpharmaxim and Lisa Campbell of SSI Strategy. 18 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze